Transfusion strategy to ABO-incompatible grafts in allogeneic hematopoietic stem cell transplantation

Xu Jin-hua; Li Xiao-feng

doi:10.3969/j.issn.2095-4344

Abstract：BACKGROUND:Hematopoietic stem cel transplantation is an important means for clinical cure of hematologic malignancies, congenital hereditary diseases and autoimmune diseases. Although ABO-incompatibility has no effects on the survival of transplanted hematopoietic stem cels, the transfusion strategy to ABO-incompatible grafts in alogeneic hematopoietic stem cel transplantation is worth studying. OBJECTIVE:To explore the antigen-antibody changes during blood conversion after ABO-incompatible hematopoietic stem cel transplantation as wel as transfusion strategies. <br> METHODS:Blood grouping, antibody detection, antibody titer determination, cross-match test were employed for antigen-antibody monitoring during blood conversion and pre-transfusion compatibility detection in 24 cases undergoing ABO-incompatible alogeneic hematopoietic stem cel transplantation. Another 30 cases undergoing ABO-compatible alogeneic hematopoietic stem cel transplantation were enroled as controls to select the appropriate blood. RESULTS AND CONCLUSION:Al of the 24 ABO-incompatible patients developed the hematopoietic reconstitution after transplantation, but both major and major-minor ABO incompatibility were different from ABO compatibility in the time of erythrocytic recovery (P < 0.05). According to the changes of ABO antigen and antibody during the blood conversion, the patients of major ABO incompatibility were selected the red blood cels of their own type, the patients of minor ABO incompatibility were selected the red blood cels of the blood group from patients to donors gradualy, and the patients of major-minor ABO incompatibility were selected the red blood cels from O-type blood to donor’s type gradualy. None of the 24 recipients presented hemolytic reaction during transplantation and after transfusion. Therefore, the transfusion strategy to ABO-incompatible grafts in alogeneic hematopoietic stem cel transplantation is dynamicaly varied according to the changes of patient’s ABO antigen and antibody, and evaluating the recovery of erythropoietic system can guide blood component selection, avoid hemolytic transfusion reaction, and insure the safety of hematopoietic stem cel transplantation.